NCT02819141View on ClinicalTrials.gov

Self-management of Sedative Therapy by Ventilated Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Critical IllnessAnxietyRespiratory Failure
Interventions
DRUG

Dexmedetomidine

Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.

Trial Locations (2)

55455

School of Medicine, University of Minnesota, Minneapolis

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

University of Minnesota

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER